GlobeImmune Announces Updates
November 17, 2016 17:49 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 17, 2016) - GlobeImmune, Inc. today provided an update on the Company's business:Gilead Sciences, Inc. has terminated the collaboration and license agreement...
GlobeImmune Announces Delisting and Deregistration of Common Stock
July 05, 2016 16:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - July 05, 2016) - GlobeImmune, Inc. (NASDAQ: GBIM) On June 30, 2016, the board of directors (the "Board") of GlobeImmune, Inc. (the "Company") made a determination to...
GlobeImmune Announces Updates and Financial Results for First Quarter 2016
May 12, 2016 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 12, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Updates and Financial Results for Full Year 2015
March 16, 2016 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 16, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
November 13, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
August 14, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
August 13, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
UPDATE - Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
August 04, 2015 09:27 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to...
Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
August 04, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively...
GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring
June 10, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - June 10, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options for the company. In conjunction with this process, the Board...